7α,24-dihydroxy-5β-cholane | 17041-51-9

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 7α,24-dihydroxy-5β-cholane
• 英文别名: 7α-hydroxy-5β-cholan-24-ol；5β-cholan-7α,24-diol；7α,24-Dihydroxy-5β-cholan；7α,24-Dihydroxycholan；(5I(2),7I+/-)-Cholane-7,24-diol；(5S,7R,8R,9S,10S,13R,14S,17R)-17-[(2R)-5-hydroxypentan-2-yl]-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-7-ol
• CAS: 17041-51-9
• 化学式: C₂₄H₄₂O₂
• 分子量: 362.596
• InChiKey: VGAZUFHPGVCDDW-QXKARQELSA-N

物化性质

• 沸点：
  474.5±18.0 °C(Predicted)
• 密度：
  1.024±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  6.8
• 重原子数：
  26
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  40.5
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  7α,24-dihydroxy-5β-cholane 在 jones reagent 作用下， 以 丙酮 为溶剂， 反应 0.33h， 生成 methyl 7-keto-5β-cholan-24-oate
  参考文献：
  名称：

  Sawaya, Takuji; Kimura, Michiya, Chemical and pharmaceutical bulletin, 1983, vol. 31, # 4, p. 1207 - 1212

  摘要：

  DOI：
• 作为产物：
  描述：

  (5beta,7alpha)-7-羟基胆烷-24-酸 在 lithium aluminium tetrahydride 作用下， 以 乙醚 为溶剂， 生成 7α,24-dihydroxy-5β-cholane
  参考文献：
  名称：

  Ahmed,S. et al., Australian Journal of Chemistry, 1971, vol. 24, p. 521 - 547

  摘要：

  DOI：

文献信息

• CHOLANE DERIVATIVES FOR USE IN THE TREATMENT AND/OR PREVENTION OF FXR AND TGR5/GPBAR1 MEDIATED DISEASES
  申请人：BAR PHARMACEUTICALS S.R.L.

  公开号：US20170190731A1

  公开（公告）日：2017-07-06

  The present invention relates to compounds having cholane scaffolds of formula (I), said compounds for use in the treatment and/or prevention of FXR and TGR5/GPBAR1 mediated diseases.

  本发明涉及具有胆固醇骨架的化合物（I）的公式，所述化合物用于治疗和/或预防FXR和TGR5 / GPBAR1介导的疾病。
• Cholane derivatives for use in the treatment and/or prevention of FXR and TGR5/GPBAR1 mediated diseases
  申请人：BAR PHARMACEUTICALS S.R.L.

  公开号：US10407462B2

  公开（公告）日：2019-09-10

  The present invention relates to compounds having cholane scaffolds of formula (I), said compounds for use in the treatment and/or prevention of FXR and TGR5/GPBAR1 mediated diseases.

  本发明涉及具有式（I）胆烷支架的化合物，所述化合物用于治疗和/或预防 FXR 和 TGR5/GPBAR1 介导的疾病。
• [EN] CHOLANE DERIVATIVES FOR USE IN THE TREATMENT AND/OR PREVENTION OF FXR AND TGR5/GPBAR1 MEDIATED DISEASES<br/>[FR] DÉRIVÉS DE CHOLANE À UTILISER DANS LE TRAITEMENT ET/OU LA PRÉVENTION DE MALADIES MÉDIÉES PAR FXR ET TGR5/GPBAR1
  申请人：BAR PHARMACEUTICALS S R L

  公开号：WO2015181275A8

  公开（公告）日：2016-02-18
• Exploitation of Cholane Scaffold for the Discovery of Potent and Selective Farnesoid X Receptor (FXR) and G-Protein Coupled Bile Acid Receptor 1 (GP-BAR1) Ligands
  作者：Carmen Festa、Barbara Renga、Claudio D’Amore、Valentina Sepe、Claudia Finamore、Simona De Marino、Adriana Carino、Sabrina Cipriani、Maria Chiara Monti、Angela Zampella、Stefano Fiorucci

  DOI：10.1021/jm501273r

  日期：2014.10.23

  Nuclear and G-protein coupled receptors are considered major targets for drug discovery. FXR and GP-BAR1, two bile acid-activated receptors, have gained increasing consideration as druggable receptors. Because endogenous bile acids often target both receptor families, the development of selective ligands has been proven difficult, exposing patients to side effects linked to an unwanted activation of one of the two receptors. In the present study, we describe a novel library of semisynthetic bile acid derivatives obtained by modifications on the cholane scaffold. The pharmacological characterization of this library led to the discovery of 7a-hydroxy-5 beta-cholan-24-sulfate (7), 6 beta-ethyl-3a,7 beta-dihydroxy-5 beta-cholan-24-ol (EUDCOH, 26), and 6a-ethyl-3a, 7a-dihydroxy-24-nor-5 beta-cholan-23-ol (NorECDCOH, 30) as novel ligands for FXR and GP-BAR1 that might hold utility in the treatment of FXR and GP-BAR1 mediated disorders.
• Ahmed,S. et al., Australian Journal of Chemistry, 1971, vol. 24, p. 521 - 547
  作者：Ahmed,S. et al.

  DOI：——

  日期：——